Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tirzepatide Autoinjector vs Prefilled Syringe in Healthy Subjects
NCT04004988Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tirzepatide in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity and Maximum Observed Plasma Concentration. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT04004988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04004988.